Trocoxil 75 mg Chewable Tablets for Dogs

Do not administer other NSAIDs or glucocorticoids concurrently or within 1
month of the last administration of Trocoxil.

i. Special precautions for use in animals
Mavacoxib exhibits an extended plasma half life (up to > 80 days, see section
5.2) due to its low rate of elimination. This corresponds to a duration of effect of
1-2 months after administration of the second dose (and following doses). Care
should be taken to avoid treatment of animals that might not tolerate prolonged
NSAID exposure. A maximum treatment administration of 6.5 months
continuous therapy is recommended so as to manage plasma levels of
mavacoxib in animals which exhibit reduced elimination
Animals should undergo a thorough clinical examination before commencing
treatment with Trocoxil and appropriate laboratory tests to monitor haematology
and clinical chemistry are recommended. Animals with evidence of impaired
renal or hepatic function, or with evidence of a protein or blood losing
enteropathy are not suitable for treatment with Trocoxil. It is recommended to
repeat the clinical examination one month after commencing treatment with
Trocoxil and prior to administration of the third dose with additional monitoring
of clinical pathology as appropriate during treatment.
Mavacoxib is excreted via bile and in dogs with hepatic disorders reduced
elimination and thus excessive accumulation could occur. For this reason, dogs
with hepatic disorders should not be treated.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is
a potential risk of increased renal toxicity. Concurrent administration of
potentially nephrotoxic medicinal products should be avoided.
Ensure appropriate hydration and haemodynamic status when animals
receiving Trocoxil undergo anaesthesia and/or surgical procedures or develop
conditions which may result in dehydration or compromised haemodynamic
status. The key aim of intervention is to maintain renal perfusion. Patients with

Issued: October 2023
AN: 01444/2022
underlying renal disease may experience exacerbation or decompensation of
their renal disease while on NSAID therapy. (See also section 4.6).
ii. Special precautions to be taken by the person administering the
veterinary medicinal product to animals
In case of accidental self-ingestion, seek medical advice immediately and show
the package leaflet or the label to the physician.
Ingestion of the product may be harmful for children, and prolonged
pharmacological effects leading to e.g. gastrointestinal disorders may be
observed. To avoid accidental ingestion, administer the tablet to the dog
immediately after removal from the blister packaging.
People with known hypersensitivity to NSAIDs should avoid contact with the
veterinary medicinal product.
Do not eat, drink, or smoke when handling the product. Wash hands after
handling the product.
Special precautions for the protection of the environment:
Not applicable.